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tion of renal cell carcinoma (RCC) with tumor throm-
bus. They also reported their experience of patch grafting
(n ! 11) and IVC interposition (n ! 6) of the IVC
during RCC tumor thrombus surgery.1
We have used liver transplant techniques to gain ad-
equate exposure of the upper abdomen when dealing with
urological tumors with caval involvement.2-4 We have
previously published the use of natural venovenous by-
pass (VVP) in patients with advanced tumor thrombus.5
The natural bypass involved the preservation and use of
collateral veins created by the longstanding obstruction
of the IVC. In most of our cases, IVC clamping above
and below the tumor thrombus did not result in systemic
hypotension and a VVP was not necessary.
Moreover, we have learned from experience that pa-
tients with chronic obstruction of the IVC have less
hemodynamic instability compared with acute obstruc-
tions.6 With chronic obstruction of the IVC, collaterals
develop with time and compensate the venous return
mainly through the azygos and hemiazygos system. It is
important to not interrupt the competitive collaterals
that have developed with time, particularly on the con-
tralateral side of the great vessels. In general, with
chronic IVC occlusion, complications such as venous
congestion and lymphatic extravasation are manageable.
In the last decade we selectively reconstructed the IVC
with vascular graft in few patients because of long seg-
mental resections. However, we have safely performed
surgical interruption of the IVC in several selected pa-
tients without significant postoperative morbidity. IVC
graft interposition and reconstruction are time-con-
suming and technically demanding procedures that are
not without complications. Our experience indicates
that patch grafting or IVC interposition can be safely
avoided for the majority of the advanced tumor throm-
bus cases, thereby simplifying the operation and reduc-
ing morbidity.
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Re: Samplaski et al.: Inclusion of Erectile
Domain to UPOINT Phenotype Does Not
Improve Correlation With Symptom
Severity in Men With Chronic Prostatitis/
Chronic Pelvic Pain Syndrome (Urology
2011;78:653-658)
TO THE EDITOR:
Samplaski et al1 have recently reported the results of a
retrospective study including 100 patients affected by
chronic prostatitis/chronic pelvic pain syndrome (CP/
CPPS). From their findings, the authors questioned some
of the conclusions of a study performed by our research
group of a cohort of European patients,2 aimed at test-
ing the novel urinary, psychosocial, organ specific,
infection, neurologic/systemic, tenderness of skeletal
muscles (UPOINT) phenotyping system for CP/CPPS.3
Because it is widely acknowledged that sexual dysfunc-
tion (SD) is an important component of the clinical
phenotype of CP/CPPS,4 we investigated the addition of
a specific SD domain to the UPOINT system. Our study
population included 937 Italian patients from a second-
ary referral center, with mild/moderate SD, and 290 men
from a German tertiary center, who were characterized by
a more severe SD profile. We found that addition of an
“S” domain to the UPOINT system significantly im-
proved the correlation between the total score of the
National Institutes of Health-Chronic Prostatitis Symp-
tom Index (CPSI) and the stepwise-increasing number of
UPOINTS domains in German patients. In the Italian
and merged cohorts, the same correlation remained
highly significant, with or without the “S” domain.
Thus, the addition of a sexual dysfunction domain
allowed us to improve the correlation observed in our
“German” patients without disrupting the correlation ob-
served in the “Italian” patients, who presented with
milder sexual symptoms (this is perhaps the specific case
of the patients studied by Samplaski et al1). We believe
this represented an overall improvement of the UPOINT
system and an extension of its consistency for more
diverse categories of patients.
The results shown by Samplaski et al1 raise the follow-
ing questions:
1. Is 0.27 an acceptable coefficient to establish a corre-
lation between UPOINT domains and CPSI scores?
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2. Is a subjective yes/no answer to the question “do you
have erection problems?” sufficient to exhaustively
describe the SD profile of a patient? A validated
questionnaire was used in our study to assess erectile
dysfunction and also orgasmic dysfunction and
changes in libido.
3. The authors demonstrated by univariate regression
analysis that an SD domain does not significantly
alter the CPSI total score in their patient popula-
tion. However, not even the prostate-specific “O”
domain of UPOINT could significantly alter the
scores of the prostate-specific CPSI test. Is this
population sufficiently representative of a condition
such as CP/CPPS?
In conclusion, we stand for the inclusion of the SD
phenotype in UPOINT or in any other CP/CPPS phe-
notyping system. If a “stand-alone” sexual domain is not
acceptable to Samplaski et al,1 we propose that a SD item
should be included within 1 of the 6 UPOINT domains.
We have simulated in our patient cohorts the inclusion
of an erectile dysfunction item in the “O” or “P”
UPOINT domains. Also, in this case the correlation
between the total score of the CPSI and the number of
UPOINT domains was significantly improved in the Ger-
man tertiary-referral patients presenting with severe SD
(Table 1) and, again, the data shown by the Italian
population, presenting with milder symptoms, were not
affected by this modification.
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Reply by the Authors
TO THE EDITOR:
Thank you for the opportunity to respond to the letter
from Dr. Magri and colleagues. We believe a careful read
of our article, particularly the Methods and Discussion,
Table 1. Analysis of correlation between CPSI total scores and number of positive UPOINT domains stratified by varying
placement of sexual dysfunction
Cohort Statistical Analysis
NIH-CPSI Total Score
UPOINT, No
SD
UPOINT, SD
in “P”
Domain
UPOINT, SD
in “O”
Domain UPOINTS
German Spearman’s rho (P value) 0.8 (.104) 0.9 (.037) 0.9 (.037) 1 (".0001)
Kendall’s ! (P value) 0.6 (.14) 0.8 (.05) 0.8 (.05) 1 (.01)
Pearson’s correlation
coefficient (P value)
0.73 (.078) 0.82 (.04) 0.84 (.036) 0.96 (.004)
P value, ANOVA .15 .087 .072 .008
Italian Spearman’s rho (P value) 1 (".0001) 1 (".0001) 1 (".0001) 1 (.0001)
Kendall’s ! (P value) 1 (.014) 1 (.014) 0.1 (".0001) 1 (.005)
Pearson’s correlation
coefficient (P value)
0.99 (.0003) 0.99 (.0003) 0.99 (.0003) 0.98 (.0001)
P value, ANOVA .0006 .0007 .0006 .0002
Merged Spearman’s rho (P value) 1 (".0001) 1 (".0001) 1 (".0001) 1 (.001)
Kendall’s ! (P value) 1 (.014) 1 (.014) 1 (.014) 1 (.005)
Pearson’s correlation
coefficient (P value)
0.98 (.001) 0.98 (.0009) 0.99 (.0001) 0.98 (.0001)
P value, ANOVA .002 .002 .0003 .0002
Cronbach’s " 0.48 0.47 0.47 0.47
CPSI, Chronic Prostatitis Symptom Index; NIH, National Institutes of Health; UPOINT, urinary, psychosocial, organ specific, infection,
neurologic/systemic, tenderness of skeletal muscles; ANOVA, analysis of variance.
Nonparametric and parametric correlation coefficients, ANOVA, and reliability coefficients (Cronbach’s ") presented.
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